- Home
- TCRX vs HYFT Comparison
TCRX vs HYFT Comparison
Compare TCRX & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | HYFT |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 56.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TCRX | HYFT |
|---|---|---|
| Price | $0.19 | $1.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $1.00 | ★ $4.33 |
| AVG Volume (30 Days) | ★ 579.6K | 289.2K |
| Earning Date | 11-11-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | $12.86 |
| Revenue Next Year | N/A | $22.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.18 | $0.99 |
| 52 Week High | $2.14 | $3.00 |
Technical Indicators
Market Signals| Indicator | TCRX | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 27.68 | 37.54 |
| Support Level | N/A | $1.03 |
| Resistance Level | $0.37 | $1.50 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 14.81 | 14.74 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About HYFT MindWalk Holdings Corp.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.